AstraZeneca Partners With Actor Mark-Paul Gosselaar to Promote Cancer Biomarker Testing Awareness

0
50
Mark-Paul Gosselaar

WILMINGTON, Del.–AstraZeneca has partnered with actor Mark-Paul Gosselaar to launch a national public health awareness campaign aimed at encouraging cancer patients and their families to learn about biomarker testing, which can help doctors make more personalized treatment decisions.

The campaign, called Meet Your Mark, encourages people diagnosed with cancer to discuss biomarker testing with their healthcare providers as part of their treatment planning.

Gosselaar, known for his television career, draws on his familiar on-screen “time out” moments to encourage patients to pause, ask questions and become more involved in decisions about their cancer care.

“Having seen loved ones navigate cancer diagnoses, I felt it was important to spread the word about biomarker testing. It’s a process that may help people better understand their cancer and help healthcare providers match them with a treatment that may target their specific biomarker. By bringing back my history of calling a ‘time out’, we’re empowering those living with cancer to take a moment to ask their doctor about biomarker testing, enabling them to play a more active role in their care,” Gosselaar said.

Biomarker testing examines biological characteristics, including genes, proteins and other substances, that can provide information about a patient’s cancer. These markers may be identified through blood or tissue samples and can help doctors understand how a cancer might behave or respond to specific treatments.

The information can also help determine whether patients may benefit from targeted therapies or immunotherapies. Even among people diagnosed with the same type of cancer, differences in tumor biology can influence treatment decisions.

According to AstraZeneca, medical organizations recommend biomarker testing for several types of cancer, including lung, breast, ovarian, prostate and colorectal cancers, as well as melanoma and certain blood cancers.

The company cited a study involving more than 1,200 people affected by cancer in which more than 75% of respondents who underwent biomarker testing said the results provided their doctors with valuable information for treatment planning.

Despite established medical guidelines, biomarker testing remains underutilized in the United States. AstraZeneca said only about one-third of patients with advanced cancer undergo testing.

The campaign seeks to address that gap by encouraging patients and caregivers to ask whether biomarker testing is appropriate for their diagnosis and treatment options.

“At AstraZeneca, our goal is to one day eliminate cancer as a cause of death. We believe biomarker testing has a critical role to play in making this possible by providing doctors with valuable insights to guide cancer care. Through Meet Your Mark and our partnership with Mark-Paul Gosselaar, we’re calling attention to biomarkers as a powerful tool in navigating a cancer diagnosis, supporting our broader commitment to cancer care,” said Mohit Manrao, senior vice president and head of U.S. oncology at AstraZeneca.

In addition to Gosselaar’s participation, Meet Your Mark features personal accounts from people living with cancer and perspectives from healthcare professionals about the potential role of biomarker testing in treatment decisions.

The campaign emphasizes that patients can take a more active role in their care by discussing testing options with their medical teams and understanding how the results may influence their treatment plans.

Leave A Reply

Please enter your comment!
Please enter your name here